Zacks Investment Research Lowers Inovalon (INOV) to Sell
Zacks Investment Research lowered shares of Inovalon (NASDAQ:INOV) from a hold rating to a sell rating in a research report released on Wednesday.
According to Zacks, “Inovalon Holdings, Inc. is a technology company which provides cloud-based data analytics and data-driven intervention platforms for healthcare sector. The company operates through IT and services group. IT operations group manages the process steps from data receipt through to the generation of analytical outputs and services operations group manages the process steps applied to achieve impact through its data-driven intervention platforms. It serves health plans, hospitals, physicians, patients, pharmaceutical companies and researchers. Inovalon Holdings, Inc. is headquartered in Bowie, Maryland. “
Other equities research analysts have also recently issued reports about the stock. BidaskClub cut shares of Inovalon from a sell rating to a strong sell rating in a report on Thursday, December 14th. TheStreet upgraded shares of Inovalon from a d+ rating to a c- rating in a report on Thursday, October 5th. KeyCorp reiterated a hold rating on shares of Inovalon in a report on Tuesday, September 12th. Finally, Morgan Stanley upgraded shares of Inovalon from an underweight rating to an equal weight rating and upped their price objective for the stock from $9.00 to $14.00 in a report on Tuesday, September 12th. Three analysts have rated the stock with a sell rating and five have given a hold rating to the stock. The stock presently has an average rating of Hold and an average price target of $12.00.
Shares of Inovalon (NASDAQ:INOV) opened at $14.20 on Wednesday. The stock has a market cap of $2,049.50, a price-to-earnings ratio of 66.90, a P/E/G ratio of 3.46 and a beta of 1.23. Inovalon has a fifty-two week low of $10.45 and a fifty-two week high of $17.80. The company has a quick ratio of 5.62, a current ratio of 5.62 and a debt-to-equity ratio of 0.31.
Inovalon (NASDAQ:INOV) last issued its quarterly earnings data on Wednesday, November 1st. The technology company reported $0.09 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.08 by $0.01. The firm had revenue of $115.90 million during the quarter, compared to analysts’ expectations of $114.79 million. Inovalon had a net margin of 4.07% and a return on equity of 4.63%. Inovalon’s revenue for the quarter was up 10.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.10 earnings per share. analysts anticipate that Inovalon will post 0.25 EPS for the current fiscal year.
In other Inovalon news, President Robert A. Wychulis sold 85,828 shares of the company’s stock in a transaction dated Tuesday, December 5th. The shares were sold at an average price of $15.54, for a total transaction of $1,333,767.12. Following the completion of the sale, the president now directly owns 466,286 shares in the company, valued at $7,246,084.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Shauna L. Vernal sold 5,908 shares of the company’s stock in a transaction dated Friday, November 17th. The shares were sold at an average price of $16.01, for a total transaction of $94,587.08. Following the sale, the insider now owns 47,309 shares of the company’s stock, valued at $757,417.09. The disclosure for this sale can be found here. 48.28% of the stock is owned by corporate insiders.
A number of hedge funds have recently added to or reduced their stakes in the business. Advisor Group Inc. boosted its holdings in Inovalon by 24.8% during the second quarter. Advisor Group Inc. now owns 10,191 shares of the technology company’s stock valued at $134,000 after acquiring an additional 2,023 shares during the period. PNC Financial Services Group Inc. boosted its holdings in Inovalon by 1.5% during the second quarter. PNC Financial Services Group Inc. now owns 202,895 shares of the technology company’s stock valued at $2,667,000 after acquiring an additional 2,945 shares during the period. Oppenheimer Asset Management Inc. boosted its holdings in Inovalon by 3.4% during the third quarter. Oppenheimer Asset Management Inc. now owns 104,171 shares of the technology company’s stock valued at $1,776,000 after acquiring an additional 3,388 shares during the period. Dimensional Fund Advisors LP boosted its holdings in Inovalon by 5.4% during the third quarter. Dimensional Fund Advisors LP now owns 75,204 shares of the technology company’s stock valued at $1,282,000 after acquiring an additional 3,831 shares during the period. Finally, Voya Investment Management LLC boosted its holdings in Inovalon by 18.7% during the second quarter. Voya Investment Management LLC now owns 28,393 shares of the technology company’s stock valued at $373,000 after acquiring an additional 4,469 shares during the period. Institutional investors own 28.08% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Zacks Investment Research Lowers Inovalon (INOV) to Sell” was posted by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://www.watchlistnews.com/zacks-investment-research-lowers-inovalon-inov-to-sell/1805729.html.
Inovalon Company Profile
Inovalon Holdings, Inc (Inovalon) is a technology company. The Company provides cloud-based platforms empowering a data-driven transformation from volume-based to value-based models to the healthcare industry. Leveraging large-scale data interconnectivity capabilities, unparalleled proprietary data sets, advanced analytics, data-driven intervention systems, and subject matter expertise, Inovalon enables the assessment and improvement of clinical and quality outcomes and financial performance across the healthcare ecosystem.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inovalon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovalon and related companies with MarketBeat.com's FREE daily email newsletter.